A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis

J Am Acad Dermatol. 2017 Oct;77(4):753-755. doi: 10.1016/j.jaad.2017.05.055.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drugs, Investigational / therapeutic use*
  • Female
  • Follow-Up Studies
  • Galectin 3 / drug effects*
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Patient Safety
  • Pectins / therapeutic use*
  • Pilot Projects
  • Psoriasis / diagnosis*
  • Psoriasis / drug therapy*
  • Treatment Outcome

Substances

  • Drugs, Investigational
  • Galectin 3
  • Pectins
  • belapectin